Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 08, 2023 17:08 ET | Source: Quoin Pharmaceuticals, Inc.

Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and Full Year 2022 Financial Results

Quoin announced dosing of first patient in double blinded clinical study to evaluate QRX003 for Netherton SyndromeQuoin announced initiation of a second clinical trial to evaluate QRX003 in Netherton...
March 02, 2023 16:05 ET | Source: Quoin Pharmaceuticals, Inc.

Quoin Pharmaceuticals Announces 2022 Corporate Update Conference Call to be held on Thursday March 9th at 8:30am ET

ASHBURN, Va., March 02, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan...
February 22, 2023 08:39 ET | Source: Quoin Pharmaceuticals, Inc.

Quoin Pharmaceuticals Announces Pricing of $7.0 Million Public Offering

ASHBURN, Va., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan...
December 13, 2022 08:30 ET | Source: Quoin Pharmaceuticals, Inc.

Quoin Pharmaceuticals Announces Dosing of First Patient in Clinical Trial in Netherton Syndrome

Company’s Second Netherton Syndrome Clinical Study has been Cleared by FDA to Initiate Testing All Six Target Clinical Sites are on Track to be Fully Opened by Year End ASHBURN, Va., Dec. 13, 2022 ...
November 10, 2022 08:30 ET | Source: Quoin Pharmaceuticals, Inc.

Quoin Pharmaceuticals Provides Corporate Update and Announces Third Quarter 2022 Financial Results

Company completed a public offering for aggregate gross proceeds of $16.8 millionMajority of clinical sites now open in clinical study to evaluate QRX003 for Netherton SyndromeQuoin announced plans to...
November 03, 2022 07:00 ET | Source: Quoin Pharmaceuticals, Inc.

Quoin Pharmaceuticals Announces Updated Timing of Third Quarter 2022 Corporate Update Conference Call to be held on Thursday November 10th

ASHBURN, Va., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan...
November 01, 2022 08:30 ET | Source: Quoin Pharmaceuticals, Inc.

Quoin Pharmaceuticals to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 10th

ASHBURN, Va., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan...
October 18, 2022 08:30 ET | Source: Quoin Pharmaceuticals, Inc.

Quoin Pharmaceuticals Announces Plans to Initiate a Second Clinical Trial in Netherton Syndrome Patients

ASHBURN, Va., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases,...
September 13, 2022 08:30 ET | Source: Quoin Pharmaceuticals, Inc.

Quoin Pharmaceuticals Establishes Patient Specific Website for Ongoing Netherton Syndrome Clinical Study

ASHBURN, Va., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, has...
August 18, 2022 07:00 ET | Source: Quoin Pharmaceuticals, Inc.

Quoin Pharmaceuticals Provides Corporate Update and Announces Second Quarter 2022 Financial Results

Initiates clinical trial evaluating lead product candidate, QRX003 for Netherton SyndromeExpands number of commercial partnerships to eight, covering 60 countriesSigns Research Agreement to develop a...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right